BioInvent (BOVNF) Interim Report 1 January – 31 March 2013  
4/25/2013 8:15:54 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Regulatory News:

BioInvent (STO:BINV):

Important events in the first quarter and after the end of the reporting period

•Positive results were reported in the phase I study of BI-505 in patients with multiple myeloma. The candidate drug was well tolerated and indicated therapeutic effect.

•The first patient was dosed in April in an initial phase II study of BI-505.

Help employers find you! Check out all the jobs and post your resume.